Back to Search
Start Over
Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial
- Source :
- Ayoobi, F, Moghadam-Ahmadi, A, Amiri, H, Vakilian, A, Heidari, M, Farahmand, H, Fathollahi, M S, Fatemi, I, Shafiei, S A, Alahtavakoli, M & Shamsizadeh, A 2019, ' Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: A randomized placebo-controlled clinical trial ', Phytomedicine, vol. 52, pp. 89-97 . https://doi.org/10.1016/j.phymed.2018.06.017, Phytomedicine, 52, 89-97. Urban und Fischer Verlag Jena
- Publication Year :
- 2019
- Publisher :
- Elsevier BV, 2019.
-
Abstract
- Background Multiple sclerosis (MS) is a neurological disease for which to date there is no cure and the existing disease-modifying drugs just slow down the disease progression. Purpose In this clinical trial we evaluated the efficacy of Achillea millefolium (A. millefolium) aqueous extract in MS patients. Methods A triple-blind randomized placebo-controlled parallel group trial was conducted on 75 MS patients. The patients were randomized into three groups including placebo and two groups receiving A. millefolium with two different doses, i.e. 250 mg/day and 500 mg/day, for 1 year. The primary outcome was the annualized relapse rate. Also, number and volume of lesions were obtained from magnetic resonance imaging (MRI) scans. Furthermore, we performed a comprehensive neurological and cognitive tests as follows: changes in the expanded disability status scale (EDSS), the multiple sclerosis functional composite (MSFC), fatigue severity scale (FSS), Ashworth spasticity assessment, Beck depression test, State-trait anxiety inventory (STAI), mini-mental status examination (MMSE), Wisconsin card sorting test (WCST), tower of London test (TOL), word-pair learning, paced auditory serial addition task (PASAT) and standard laboratory tests. Results This study showed one year administration of A. millefolium (both doses) decreased the annual relapse rate in MS patients. The mean volume change of lesions significantly decreased in the 500 mg A. millefolium group. The add-on therapy also increased time to first relapse and the MSFC z-score; it decreased the EDSS score and improved performance in word-pair learning, PASAT, and WCST. Conclusion We found beneficial effects of A. millefolium aqueous extract as an add-on therapy in MS patients.
- Subjects :
- Adult
Male
medicine.medical_specialty
Multiple Sclerosis
Pharmaceutical Science
Placebo
03 medical and health sciences
0302 clinical medicine
Wisconsin Card Sorting Test
Recurrence
Internal medicine
Drug Discovery
Tower of London test
medicine
Humans
Depression (differential diagnoses)
030304 developmental biology
Pharmacology
0303 health sciences
Expanded Disability Status Scale
Plant Extracts
business.industry
Multiple sclerosis
medicine.disease
Achillea
Clinical trial
Complementary and alternative medicine
Multiple sclerosis functional composite
030220 oncology & carcinogenesis
Disease Progression
Molecular Medicine
Female
business
Phytotherapy
Subjects
Details
- ISSN :
- 09447113
- Volume :
- 52
- Database :
- OpenAIRE
- Journal :
- Phytomedicine
- Accession number :
- edsair.doi.dedup.....d69e4af112ed6f2a4376052dbb7f65b7